Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Boehringer Ingelheim
ArriVent BioPharma, Inc.
Seagen Inc.
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
Daiichi Sankyo
RemeGen Co., Ltd.
Arcus Biosciences, Inc.
Erasca, Inc.
Arcus Biosciences, Inc.
Bayer
M.D. Anderson Cancer Center
Pfizer
Boehringer Ingelheim
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Genentech, Inc.
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
USWM, LLC (dba US WorldMeds)
Poseida Therapeutics, Inc.
Werewolf Therapeutics, Inc.
Roswell Park Cancer Institute
Novartis
Genentech, Inc.
Astellas Pharma Inc
Corregene Biotechnology Co., Ltd
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
Seagen Inc.
Novartis
Janssen Research & Development, LLC
Pfizer
Seagen Inc.
AbbVie
M.D. Anderson Cancer Center
Novartis
Bayer
Amgen
Merck Sharp & Dohme LLC
AstraZeneca
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
HiFiBiO Therapeutics